7:45am – 8:45am | Oxford Biomedica Ballroom
Sponsored by Thermo Fisher Scientific
APPROACHES TO IMPLEMENTING AUTOMATION IN CELL THERAPY MANUFACTURING WORKSHOP
The need for standardization and automation are critical drivers of innovation in cell therapy manufacturing. Implementation of an automated, closed workflow minimizes open processes and manual touchpoints, increases reproducibility, and improves traceability; this has the potential to reduce manufacturing failures and lower COGS thereby facilitating increased patient access. In this workshop, we sit down with industry experts to discuss various approaches to cGMP manufacturing of gene-modified cell therapies at industrial scale.
Chair:
Betty Woo, Ph.D., Vice President and General Manager, Cell and Gene Therapy, Thermo Fisher Scientific
Speakers:
Dmitry Fradkin, Director, Automation and Systems Development, Kite Pharma
Fred Parietti, Ph.D., Co-Founder and CEO, Multiply Labs
Edwin Stone, Ph.D., Head of Future Automation, TTP
7:45am – 8:45am | Aviara Salon A
Sponsored by IQVIA
THE FUTURE OF CDMO NETWORKS IN CELL AND GENE THERAPY WORKSHOP
This workshop will feature leading executives who will discuss a number of topics surrounding CDMO networks including bottlenecks in personnel capabilities and facilities along with preclinical pipeline driving capacity and workforce requirements. The session will also touch upon downstream requirements such as clinical sites capabilities, data systems, access and diversity, and regulatory bandwidth.
Chair:
Amritha Jaishankar, Ph.D., Executive Director, IQVIA Cell and Gene Therapy Translating Center
Speakers:
Eytan Abraham, Ph.D., Vice President, Business Head of Cell, Gene and Nucleic Acids Franchises, Resilience
Abla Creasey, Ph.D., Vice President, Therapeutics Development, California Institute for Regenerative Medicine (CIRM)
Haro Hartounian, Ph.D., President and CEO, BioCentriq
Alan Moore, Chief Strategy Officer, Center for Breakthrough Medicines
Nicholas Ostrout, Ph.D., Senior Advisor, Cell and Gene Therapy Corporate Strategy, Charles River Laboratories
7:45am – 8:45am | Aviara Salon B
ACCELERATING CGTX DISCOVERY AND DEVELOPMENT THROUGH USE OF ADVANCED PHENOTYPIC MODELS AND MACHINE LEARNING TECHNOLOGIES WORKSHOP
This panel will explore the ways in which next-generation engineered in-vitro models can be combined with innovations in machine learning applications to drive more rational development of complex cell and gene therapy products. Leveraging advances in in-vitro model development (ex. engineered iPSC-derived tissues) as a starting point for discovery, AI/ML platforms can help make connections and correlations between cause and effect in CGTx development at a rapid pace, ultimately driving towards faster, cheaper, and more accurate therapeutic outputs. This model is already established in the small molecule space, and this panel will explore how this will translate to the CGTx industry.
Chair:
Adam Roose, Vice President, Cell and Gene Commercial Strategy, Adjuvant Partners
Speakers:
Isaac Bentwich, M.D., Founder and CEO, Quris Technologies
Robert Deans, Ph.D., Chief Scientific Officer, Synthego
Keith James, Ph.D., Senior Vice President, Drug Discovery, insitro
Emmanouil Metzakopian, Ph.D., Vice President, Research and Development, bit.bio